OakChart

Voyager Therapeutics Inc

VYGRHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

1.76-0.07 (-3.56%)
2026-11-12 06:41 CET
Market cap
109.52 USD m
Revenue, TTM
25.11 USD m
Net income, TTM
-104.53 USD m
Free cash flow, TTM
-109.83 USD m
EPS diluted, TTM
-1.74
P/E
-
Compare

Price

VYGR against its 20, 50 and 200-day averages
2050200beat
2.003.004.001.2M2.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26VYGRclose 1.7620-day 1.8650-day 2.45200-day 3.381.76

67.9% under the 52-week high of 5.48 on 11 Mar 2026. 52-week low 1.68 on 30 Oct 2026. Last 15 sessions, 22.4% high to low

Volume 0.86× normal · the line is the 50-bar volume average

Profile

VYGR
52-week range, 2% of the way up
1.675.48

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.

IndexRUT
Employees141
IPONov 11, 2015
Beta1.16
ATR, 14d0.15
Rel volume0.86
Short float8.40%
Insider own16.27%
Inst own56.66%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap109.53M
Enterprise Value33.23M
Income-104.53M
Sales25.11M
Book/sh2.17
Cash/sh1.72
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees141
IPONov 11, 2015

Ratios

P/E-
Forward P/E-
PEG-
P/S4.36
P/B0.81
P/C1.03
P/FCF-
EV/EBITDA-
EV/Sales1.32
Quick Ratio6.81
Current Ratio6.81
Debt/Eq0.23
LT Debt/Eq0.18
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.74
EPS next Y-1.36
EPS next Q-0.35
EPS this Y20.78%
EPS next Y15.56%
EPS next 5Y14.84%
EPS past 3/5Y-19.02% -
Sales past 3/5Y-0.44% -25.09%
EPS Y/Y TTM19.88%
Sales Y/Y TTM-19.82%
EPS Q/Q15.79%
Sales Q/Q-69.97%
EarningsNov 05 AMC
EPS/Sales Surpr.4.49% -36.79%

Ownership

Insider Own16.27%
Insider Trans0.00%
Inst Own56.66%
Inst Trans2.01%
ROA-44.92%
ROE-58.90%
ROIC-65.64%
Gross Margin85.16%
Oper. Margin-450.12%
Profit Margin-416.32%
SMA20-5.53%
SMA50-28.18%
SMA200-47.87%
Trades-

Technical

Shs Outstand62.17M
Shs Float52.10M
Short Float8.40%
Short Ratio6.05
Short Interest4.38M
52W High5.48 -67.87%
52W Low1.67 5.07%
Volatility10.38% 8.52%
ATR (14)0.15
RSI (14)39.05
Beta1.16
Rel Volume0.86
Avg Volume723.77K
Volume624,180

Performance

Perf Week-5.88%
Perf Month-18.14%
Perf Quarter-45.34%
Perf Half Y-57.59%
Perf YTD-55.22%
Perf Year-58.69%
Perf 3Y-72.28%
Perf 5Y-49.57%
Perf 10Y-85.62%
Recom1.09
Target Price14.22
Prev Close1.83
Price1.76
Change %-3.56%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jan 10, 2025InitiatedCCantor FitzgeraldOverweight
Dec 02, 2024InitiatedCCitigroupBuy$12+581.8%
Nov 29, 2024ResumedWWedbushOutperform$7 → $11+525.0%
Oct 16, 2024InitiatedLLeerink PartnersOutperform$15+752.3%
Mar 26, 2024InitiatedGGuggenheimBuy$22+1,150.0%
Mar 19, 2024InitiatedHH.C. WainwrightBuy$30+1,604.5%
Mar 07, 2024InitiatedCCitigroupBuy$16+809.1%
Jan 02, 2024UpgradeWWells FargoEqual Weight → Overweight$14+695.5%
May 10, 2023InitiatedTTruistBuy$18+922.7%
Mar 10, 2023InitiatedOOppenheimerOutperform$14+695.5%

Peers

Mkt cap
TickerCompanyMkt cap
ACIUAC Immune SA230.01M
NGNENeurogene Inc519.59M
RGNXRegenxbio Inc560.06M
ALECAlector Inc391.55M
DNLIDenali Therapeutics Inc3.16B
QUREuniQure NV1.72B
PRTAProthena Corp Plc448.28M
TSHATaysha Gene Therapies Inc1.39B
ABOSAcumen Pharmaceuticals Inc16.64M
MGTXMeiraGTx Holdings plc929.69M

Insider trading

latest 14 of 24
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Jorgensen Nathan D.Former OfficerMay 15 '26Proposed Sale3.8825,00096,941May 15 04:07 PM
Jorgensen Nathan D.Former OfficerMay 15 '26Proposed Sale4.249,40639,881May 15 10:34 AM
Sandrock AlfredPresident and CEOApr 02 '26Sale3.8711,51144,548472,549Apr 03 05:55 PM
Sandrock AlfredOfficerApr 02 '26Proposed Sale3.8711,51144,597Apr 02 03:53 PM
Swartz RobinCOO & CBOFeb 24 '26Sale3.776,45824,347199,738Feb 26 09:48 AM
Sandrock AlfredPresident and CEOFeb 24 '26Sale3.7914,19753,807484,060Feb 26 09:47 AM
Jorgensen Nathan D.Chief Financial OfficerFeb 24 '26Sale3.774,66817,598151,416Feb 26 09:46 AM
Carter Todd AlfredChief Scientific OfficerFeb 24 '26Sale3.764,17415,694145,718Feb 26 09:44 AM
Carter Todd AlfredOfficerFeb 24 '26Proposed Sale3.764,17415,711Feb 24 05:17 PM
Jorgensen Nathan D.OfficerFeb 24 '26Proposed Sale3.774,66817,588Feb 24 05:16 PM
Swartz RobinOfficerFeb 24 '26Proposed Sale3.776,45824,335Feb 24 05:10 PM
Sandrock AlfredOfficerFeb 24 '26Proposed Sale3.7914,19753,852Feb 24 05:09 PM
Swartz RobinCOO & CBOFeb 18 '26Sale3.443,88213,354206,196Feb 20 04:04 PM
Carter Todd AlfredChief Scientific OfficerFeb 18 '26Sale3.443,30111,355149,892Feb 20 04:03 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IBBiShares Biotechnology ETFAUM: 11.36B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
IWCiShares Micro-Cap ETFAUM: 1.22B
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B

News

latest 14 of 200
  • Voyager Therapeutics: Q3 Earnings Snapshot (Associated Press) -8.02% +8.43%
  • Voyager Reports Third Quarter 2026 Financial and Operating Results (GlobeNewswire)
  • Voyager's Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer's Disease to Be Featured in Poster Presentations at CTAD 2026 (GlobeNewswire)
  • Voyager Announces CEO Succession Plan, Appoints Robin Swartz President (GlobeNewswire) -7.76%
  • Voyager to Present at Upcoming Investor Conferences (GlobeNewswire)
  • Voyager Therapeutics: Q2 Earnings Snapshot (Associated Press)
  • Voyager Reports Second Quarter 2026 Financial and Operating Results (GlobeNewswire)
  • Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 (GlobeNewswire) -5.81%
  • Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer's? (Barrons.com)
  • Voyager's Tau-Targeted Gene Therapy VY1706 for Alzheimer's Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026 (GlobeNewswire)
  • Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference (GlobeNewswire)
  • Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease (GlobeNewswire)
  • Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026 (GlobeNewswire)
  • Voyager Therapeutics: Q1 Earnings Snapshot (Associated Press) -5.04%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.400-0.419-0.4004.016.3511
2026Q22026-08-06-0.400-0.484-0.4043.174.5210
2026Q12026-05-07-0.470-0.551-0.4702.598.7910
2025Q42026-03-09-0.460-0.511-0.46515.3410.4912
2025Q32025-11-10-0.470-0.521-0.47413.377.8612
2025Q22025-08-06-0.570-0.526-0.5695.209.9111
2025Q12025-05-06-0.530-0.449-0.5326.4713.9111
2024Q42025-03-11-0.590-0.367-0.5956.2816.5812
2024Q32024-11-12-0.160-0.445-0.15624.6311.7010
2024Q22024-08-06-0.180-0.409-0.17629.589.5110
2024Q12024-05-13-0.200-0.439-0.19819.509.489
2023Q42024-02-281.250-0.2891.25190.0620.637
2023Q32023-11-06-0.590-0.581-0.5914.612.917
2023Q22023-08-03-0.510-0.569-0.5104.851.607
2023Q12023-05-092.940-0.3712.942150.488.375
2022Q42023-03-07-0.610-0.546-0.613-1.553.737

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.210-1.578-1.215104.3984.07
2020FY0.9800.8460.984171.13180.41
2021FY-1.890-2.344-1.89037.4213.62
2022FY-1.210-1.156-1.21040.9146.16
2023FY2.9701.4372.969250.01179.77
2024FY-1.130-0.924-1.12780.0090.30
2025FY-2.040-2.091-2.04040.3735.53
2026FY--1.616--20.18
2027FY--1.365--39.28
2028FY--1.260--63.05
2029FY--1.303--67.50
2030FY--1.224--81.58

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0611128.813.0028.50
2026Q4S2026-11-0511008.152.5928.50
2026Q4S2026-10-2111008.152.5928.50
2026Q4S2026-08-0711158.152.5928.50
2026Q4S2026-07-25100123.352.59122.97
2026Q4S2026-07-22110121.682.59122.97
2026Q4S2026-06-29110421.682.59122.97
2026Q4S2026-06-18100323.532.59122.97
2026Q4S2026-05-25110322.872.59122.97
2026Q4S2026-05-08110322.882.59122.97
2026Q4S2026-04-30101015.255.0033.10
2026Q4S2026-03-13112014.052.0033.10
2026Q4S2026-03-1091013.275.0028.50
2026Q4S2026-01-246008.191.0019.80

Estimate history

EPS, annual-2.64-2.753-1.2150.984-1.89-1.212.969-1.127-2.04-1.7385
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.156-0.595-0.532-0.569-0.474-0.465-0.47-0.404-0.399
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual10.1357.619104.391171.12837.41540.907250.00880.00140.37425.11
Period201720182019202020212022202320242025TTM
Sales, quarterly24.6296.2786.4735.213.36515.3362.5933.1654.014
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual31.57232.36536.86537.36837.91838.61444.03854.73159.04862.173
Period201720182019202020212022202320242025MRQ
Shares, quarterly54.54254.73155.20955.43555.48259.04860.31161.27362.173
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue25.1140.3780.00250.0140.9137.41171.13104.397.62
Cost of Goods Sold Incl. D&A3.734.064.734.446.19----
Gross Profit21.3836.3175.27245.5734.72----
Selling, General and Administrative Excl. Other134.40168.16158.56123.5585.55103.27139.93153.3196.60
Research and Development103.24130.61122.6487.7354.5773.79108.75119.7364.91
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-113.02-131.84-83.29122.01-50.84-71.0227.38-51.68-91.09
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.002.600.00--
Net Income Before Taxes-104.47-119.58-64.34133.74-46.39-71.2036.74-43.60-88.47
Income Taxes0.060.140.671.410.020.000.000.00-0.18
Consolidated Net Income-104.53-119.72-65.00132.33-46.41-71.2036.74-43.60-88.29
Net Income From Continuing Operations-104.53-119.72-65.00132.33-46.41-71.2036.74-43.60-88.29
Net Income-104.53-119.72-65.00132.33-46.41-71.2036.74-43.60-88.29
EPS (Recurring)-1.69-2.04-1.132.97-1.21-1.840.98-1.21-2.75
EPS (Basic, Before Extraordinaries)-1.74-2.04-1.133.08-1.21-1.890.99-1.21-2.75
EPS (Diluted)-1.74-2.04-1.132.97-1.21-1.890.98-1.21-2.75
EBITDA-109.29-127.78-78.56126.45-44.65-65.8531.20-48.91-88.98
Non-Operating Income (Expense)8.5512.2718.9511.724.452.429.368.082.63
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.7311.6811.688.817.3811.3214.9315.6412.41
Price To Earnings Ratio--7.876.87--7.49--
Price To Sales Ratio6.605.714.091.505.722.731.564.8039.56
Gross Margin85.1689.9494.0998.2284.87----
Operating Margin-450.12-326.56-104.1148.80-124.27-189.8116.00-49.51-1,195.63
Net Margin-416.32-296.53-81.2552.93-113.45-190.2921.47-41.76-1,158.79
Shares Outstanding62.1759.0554.7344.0438.6137.9237.3736.8732.36
Market Capitalization109.52109.52309.73371.32235.50102.86267.88517.17306.04

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue4.013.172.5915.3413.375.206.476.28
Cost of Goods Sold Incl. D&A0.840.910.931.050.931.061.011.01
Gross Profit3.182.261.6614.2912.434.135.465.27
Selling, General and Administrative Excl. Other29.6028.6531.9344.2243.0340.7640.1543.57
Research and Development23.5421.1323.6734.9034.9330.2730.5134.57
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-26.42-26.39-30.27-29.93-30.59-36.62-34.69-38.30
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-24.68-24.45-27.92-27.42-27.81-33.37-30.98-33.90
Income Taxes0.020.020.010.010.080.010.040.58
Consolidated Net Income-24.69-24.47-27.94-27.43-27.89-33.38-31.02-34.49
Net Income From Continuing Operations-24.69-24.47-27.94-27.43-27.89-33.38-31.02-34.49
Net Income-24.69-24.47-27.94-27.43-27.89-33.38-31.02-34.49
EPS (Recurring)-0.40-0.40-0.47-0.47-0.47-0.57-0.53-0.59
EPS (Basic, Before Extraordinaries)-0.40-0.40-0.47-0.47-0.47-0.57-0.53-0.59
EPS (Diluted)-0.40-0.40-0.47-0.47-0.47-0.57-0.53-0.59
EBITDA-25.59-25.48-29.34-28.88-29.66-35.56-33.68-37.29
Non-Operating Income (Expense)1.751.942.352.522.793.263.714.40
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.061.921.972.782.733.272.902.95
Price To Earnings Ratio-------7.87
Price To Sales Ratio6.606.156.295.748.774.282.954.11
Gross Margin79.1771.3164.0693.1693.0379.5284.3383.90
Operating Margin-658.25-833.87-1,167.37-195.17-228.91-704.33-535.96-610.05
Net Margin-615.20-773.24-1,077.40-178.83-208.69-641.96-479.24-549.33
Shares Outstanding62.1761.2760.3159.0555.4855.4355.2154.73
Market Capitalization109.52211.47230.05218.51259.04172.10186.60309.73

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments196.45266.68230.88118.85132.54181.14281.53155.81169.05
Short Term Receivables2.924.4984.450.640.758.1118.700.201.45
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets3.335.634.355.013.418.524.436.471.29
Total Current Assets202.69276.81319.68124.50136.70197.77304.66162.48171.79
Net Property, Plant & Equipment41.6147.6630.0033.3455.3861.5046.4612.7710.28
Total Investments and Advances7.9868.581.591.511.781.782.651.361.80
Intangible Assets0.000.000.000.000.00---0.00
Other Assets0.000.000.000.000.000.540.990.410.60
Total Assets252.28393.05351.28159.36193.85261.58354.76177.03184.48
Short Term Debt Incl. Current Port. of LT Debt7.847.233.202.835.574.203.190.000.00
Accounts Payable5.014.001.602.570.570.634.071.041.02
Other Current Liabilities13.6938.5659.7067.1944.8421.9368.7530.6414.88
Total Current Liabilities26.5449.7964.5172.5950.9826.7776.0131.6715.90
Long Term Debt28.6636.5017.0920.2938.6143.4130.980.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities1.007.0033.367.459.2137.09148.2698.9134.53
Total Liabilities56.2093.29114.96100.3498.80107.26255.25130.5850.43
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity196.08299.76236.3259.0295.06154.3299.5146.45134.05
Total Shareholders Equity196.08299.76236.3259.0295.06154.3299.5146.45134.05
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity196.08299.76236.3259.0295.06154.3299.5146.45134.05
Total Liabilities & Stockholders Equity252.28393.05351.28159.36193.85261.58354.76177.03184.48
Book Value Per Share3.325.485.371.532.514.132.701.444.25
Tangible Book Value Per Share3.325.485.371.532.514.132.701.444.25
Full-Time Employees14117216212510117918512389
Price to Book Ratio0.810.942.102.941.081.735.176.555.11
Return on Assets-37.10-17.4751.83-26.28-31.2711.92-16.40-48.84-37.80
Return on Equity-48.29-24.2589.61-60.24-57.1028.95-59.74-97.83-52.37
Return on Invested Capital-53.27-19.3352.22-58.51-53.2718.58-33.41-190.09-52.74
Quick Ratio7.645.564.961.722.687.394.015.1310.81
Current Ratio7.645.564.961.722.687.394.015.1310.81

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-104.53-119.72-65.00132.33-46.41-71.2036.74-43.60-88.29
Depreciation3.734.064.734.446.195.173.822.772.12
Other Funds (Non Cash)15.6716.8310.107.717.249.217.2611.0614.58
Funds from Operations-85.13-98.83-50.17144.48-32.98-56.8247.82-29.77-71.59
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-24.06-33.6334.86-66.5620.473.29-144.5478.4455.70
Cash from Operating Activities-109.19-132.47-15.3177.92-12.51-53.52-96.7248.67-15.89
Capital Expenditures-0.64-2.60-3.52-3.26-2.49-1.61-12.10-7.72-4.30
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.030.000.000.000.000.000.000.17-
Purchase or Sale of Investments100.80128.04-91.34-138.39-4.8567.52125.09-82.9330.77
Purchase of Investments-91.05-133.93-465.69-223.97-54.85-15.12-70.40-494.23-333.23
Sale Or Maturity of Investments191.85261.97374.3585.5850.0082.63195.50411.30364.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities100.19125.45-94.86-141.64-7.3465.91113.00-90.4826.47
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock9.410.82114.0233.651.110.613.1680.994.75
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock9.410.82114.0233.651.110.613.1680.994.75
Proceedsfrom Stock Options9.040.55113.6331.790.480.580.8478.280.86
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities9.410.82114.0233.651.110.613.1680.994.75
Net Change in Cash0.40-6.213.85-30.08-18.7412.9919.4439.1815.33
Free Cash Flow-109.83-135.06-18.8374.66-15.00-55.13-108.8140.95-20.19
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow---5.04---12.23-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments106.81116.34141.48196.45208.93215.59
Short Term Receivables4.273.151.652.924.042.52
Inventories0.000.000.000.000.000.00
Other Current Assets3.355.743.863.336.629.77
Total Current Assets114.43125.23146.98202.69219.59227.89
Net Property, Plant & Equipment34.3537.1039.4341.6143.0344.89
Total Investments and Advances28.0635.2132.927.9825.7049.32
Intangible Assets--0.000.000.000.00
Other Assets0.210.210.000.000.000.00
Total Assets177.05197.75219.32252.28288.31322.10
Short Term Debt Incl. Current Port. of LT Debt6.386.887.367.847.857.64
Accounts Payable1.951.612.725.012.121.80
Other Current Liabilities8.498.207.3713.6925.5332.54
Total Current Liabilities16.8116.6817.4526.5435.4941.98
Long Term Debt24.1325.6927.2028.6630.5232.57
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities1.001.001.001.002.473.61
Total Liabilities41.9443.3845.6656.2068.4978.16
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity135.11154.38173.67196.08219.82243.94
Total Shareholders Equity135.11154.38173.67196.08219.82243.94
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity135.11154.38173.67196.08219.82243.94
Total Liabilities & Stockholders Equity177.05197.75219.32252.28288.31322.10
Book Value Per Share2.172.522.883.323.964.40
Tangible Book Value Per Share2.172.522.883.323.964.40
Full-Time Employees---141--
Price to Book Ratio0.811.221.160.991.060.63
Return on Assets-44.92-41.45-40.74-37.10-35.50-28.47
Return on Equity-58.90-54.09-52.26-48.29-46.09-37.26
Return on Invested Capital-15.51-13.59-13.91-12.20-11.14-12.07
Quick Ratio6.817.518.427.646.195.43
Current Ratio6.817.518.427.646.195.43

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-24.69-24.47-27.94-27.43-27.89-33.38
Depreciation0.840.910.931.050.931.06
Other Funds (Non Cash)4.373.593.394.324.044.55
Funds from Operations-19.49-19.97-23.61-22.06-22.92-27.77
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.18-5.87-9.81-8.20-8.13-5.49
Cash from Operating Activities-19.67-25.84-33.42-30.26-31.05-33.26
Capital Expenditures0.000.00-0.01-0.63-0.21-1.10
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.030.000.000.000.000.00
Purchase or Sale of Investments29.2515.398.1248.0535.093.04
Purchase of Investments-7.69-27.41-43.44-12.50-6.64-37.87
Sale Or Maturity of Investments36.9442.8051.5660.5541.7340.90
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities29.2715.398.1047.4234.891.93
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock3.032.913.330.140.090.51
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.032.913.330.140.090.51
Proceedsfrom Stock Options3.032.853.040.120.000.43
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities3.032.913.330.140.090.51
Net Change in Cash12.64-7.54-21.9917.303.92-30.82
Free Cash Flow-19.67-25.84-33.43-30.89-31.25-34.37

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 80.00M 2025: 40.37M
United States2024: 80.00M 2025: 40.37M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-308.40%4.4M52.1M658.33K
2026-10-157.05%3.6M51.6M585.67K
2026-09-307.70%4.0M51.6M569.99K
2026-09-157.09%3.7M51.6M581.95K
2026-08-317.34%3.8M51.6M593.61K
2026-08-147.68%3.9M51.4M629.57K
2026-07-317.09%3.6M51.4M640.25K
2026-07-157.61%3.8M50.4M604.21K
2026-06-307.09%3.6M50.4M568.94K
2026-06-157.24%3.6M50.4M567.35K
2026-05-297.43%3.7M50.4M682.98K
2026-05-156.89%3.5M50.4M667.37K
2026-04-307.28%3.7M50.3M670.79K
2026-04-157.19%3.6M49.6M720.63K
2026-03-316.73%3.3M48.9M719.09K
2026-03-136.50%3.2M48.9M667.09K
2026-02-277.00%3.2M45.6M538.58K
2026-02-137.35%3.4M45.6M536.79K
2026-01-307.45%3.4M45.8M519.97K
2026-01-157.52%3.4M45.8M502.55K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.000.004.600.000.0000.000.000.884-0.0340.001
call2.000.000.500.405.40747.000.000.606-0.0320.001
call3.000.000.200.053.42763.000.000.232-0.0160.001
call4.000.000.050.033.3431.000.000.125-0.0110.001
call5.000.000.050.013.96621.000.000.111-0.0120.001
call6.000.001.000.014.82912.000.000.105-0.0140.000
put1.000.003.800.2211.1442.000.00-0.116-0.0340.001
put2.000.000.500.403.20052.000.00-0.394-0.0320.001
put3.000.054.901.300.00083.000.00-0.768-0.0160.001
put4.000.105.000.000.0000.000.00-0.875-0.0110.001
put5.000.805.500.000.0000.000.00-0.888-0.0120.001
put6.001.706.500.000.0000.000.00-0.895-0.0130.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-058-KCurrent report2026-11-05SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-01SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-01SEC
2026-10-218-KCurrent report2026-10-20SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-31SCHEDULE 13G/ASEC
2026-07-138-KCurrent report2026-07-13SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-108-KCurrent report2026-06-09SEC
2026-06-018-KCurrent report2026-06-01SEC
2026-05-183Initial statement of beneficial ownership of securities2026-05-08SEC
2026-05-15144Filing for proposed sale of securities under Rule 144.SEC
2026-05-15144Filing for proposed sale of securities under Rule 144.SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-078-KCurrent report2026-05-07SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-28ARSAnnual report to security holders. 2025-12-31SEC
2026-04-28DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040044.55K1
2026-030000
2026-0200253.41K10
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.8.56%
MILLENNIUM MANAGEMENT LLC7.35%
ARMISTICE CAPITAL, LLC5.69%
Vestal Point Capital, LP4.34%
VANGUARD CAPITAL MANAGEMENT LLC3.88%
GEODE CAPITAL MANAGEMENT, LLC1.97%
Opaleye Management Inc.1.96%
STATE STREET CORP1.78%
TWO SIGMA INVESTMENTS, LP1.57%
VANGUARD PORTFOLIO MANAGEMENT LLC1.34%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.77%
iShares Russell 2000 ETF2.28%
VANGUARD EXTENDED MARKET INDEX FUND1.01%
Fidelity Small Cap Index Fund0.94%
iShares Russell 2000 Value ETF0.81%
VANGUARD EXPLORER FUND0.76%
iShares Biotechnology ETF0.58%
VANGUARD RUSSELL 2000 INDEX FUND0.49%
Fidelity Extended Market Index Fund0.45%
U.S. SMALL CAP PORTFOLIO0.37%

OakChart. VYGR. Cached 15 minutes.